Abstract
The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.
Keywords: glaucoma, photophobia, neurodegeneration, rehabilitation, herapy, prevention, clinical governance, multidisciplinary management, retinitis pigmentosa, Inherited retinal dystrophies
Current Genomics
Title: Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Volume: 12 Issue: 4
Author(s): Katia De Nadai, Mario R. Romano, Andrea Binotto, Ciro Costagliola, Giovanni Sato and Francesco Parmeggiani
Affiliation:
Keywords: glaucoma, photophobia, neurodegeneration, rehabilitation, herapy, prevention, clinical governance, multidisciplinary management, retinitis pigmentosa, Inherited retinal dystrophies
Abstract: The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.
Export Options
About this article
Cite this article as:
De Nadai Katia, R. Romano Mario, Binotto Andrea, Costagliola Ciro, Sato Giovanni and Parmeggiani Francesco, Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date, Current Genomics 2011; 12 (4) . https://dx.doi.org/10.2174/138920211795860125
DOI https://dx.doi.org/10.2174/138920211795860125 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes
Combinatorial Chemistry & High Throughput Screening Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Neuroprotective Effects of Lithium in Human Brain? Food for Thought
Current Alzheimer Research Preface [Hot Topic: Transmissible Spongiform Encephalopathies (Prion Diseases) Guest Editors: Xuemin Ye and Richard I. Carp ]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Peripheral Kynurenine Metabolism in Focal Dystonia
Medicinal Chemistry Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia
Current Pharmaceutical Design Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration
Current Alzheimer Research Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry Small Molecule Fluorescent Ligands as Central Nervous System Imaging Probes
Mini-Reviews in Medicinal Chemistry Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research Remodeling Chromatin and Stress Resistance in the Central Nervous System: Histone Deacetylase Inhibitors as Novel and Broadly Effective Neuroprotective Agents
Current Drug Targets - CNS & Neurological Disorders Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Polyglutamine Protein Trafficking and Neurodegeneration
Current Genomics Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets